Drug Interaction Report

Consumer information for this interaction is not currently available.

GENERALLY AVOID: Coadministration with potent inhibitors of CYP450 2D6 may significantly increase the plasma concentrations of topical sofpironium, which has been shown to be partially metabolized by the isoenzyme. In a pharmacokinetic study in patients with primary axillary hyperhidrosis, sofpironium systemic exposure (AUC) and peak plasma concentration (Cmax) increased approximately 2 -fold following concomitant use with the potent CYP450 2D6 inhibitor paroxetine at a 20 mg oral dose.

MANAGEMENT: Coadministration of topical sofpironium with potent CYP450 2D6 inhibitors should generally be avoided. If coadministration is required, monitor for sofpironium-related adverse effects which include blurred vision, urinary retention, difficulty controlling body temperature in warm environments, and dry mouth.

Food can enhance the levels of cinacalcet in your body. Cinacalcet should be taken just after eating food. Do not take it on an empty stomach. This will make it easier for your body to absorb the medication. Do not crush, chew, or break the tablets. Swallow them whole.